Biotechnology
Understanding Autism Spectrum Disorder in Children: Insights and Advances in Treatment

New York, March 08, 2024 - PRISM MediaWire - Autism Spectrum Disorder (ASD) is a complex neurodevelopmental condition characterized by challenges in social interaction, communication, and repetitive behaviors. It affects individuals differently and can range from mild to...

8 March 2024

Biotechnology
Lipella Pharmaceuticals to Progress Development of Oral Graft-versus-Host-Disease Treatment Candidate

New York, March 06, 2024 - PRISM MediaWire - "Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) secures FDA Approval for Investigational New Drug (IND) Application, Advancing Clinical Testing of LP-410 for Oral Graft-Versus-Host Disease (GvHD) Treatment. Clinical Study Set to ...

6 March 2024

Biotechnology
IceCure's ProSense® Achieves Complete Tumor Reduction in Early-Stage Breast Cancer

New York, March 06, 2024 - PRISM MediaWire - IceCure Medical Ltd. (Nasdaq: ICCM) has disclosed novel findings from an initial, autonomous breast cancer investigation, revealing a median tumor reduction of 100% at both six and twelve months subsequent to cryoablation in w...

6 March 2024

Biotechnology
Quoin Pharmaceuticals Expands Rare Disease Clinical Trials to Encompass Teen Patients

New York, March 04, 2024 - PRISM MediaWire - Clinical-stage biotechnology firm Quoin Pharmaceuticals (Nasdaq: QNRX) has obtained FDA clearance to enroll subjects aged 14 years and above into its two ongoing clinical trials for QRX003. These trials are dedicated to assess...

4 March 2024

Biotechnology
NeuroBo Pharmaceuticals to Commence Clinical Trial Addressing Obesity

New York, March 04, 2024 - PRISM MediaWire - NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO) has obtained Institutional Review Board (IRB) approval to advance its Phase 1 clinical trial of DA-1726, targeting obesity treatment. Anticipated commencement of patient randomizati...

4 March 2024

Biotechnology
Enveric Biosciences Makes Strides in Mental Health Treatment, Witnesses 127% Surge in Shares through Out-Licensing of Compound Classes

New York, N.Y., February 29, 2024 - PRISM MediaWire - Enveric Biosciences (NASDAQ: ENVB), a biotechnology firm specializing in the development of neuroplastogenic small-molecule therapeutics for mental health disorders, has announced the initiation of negotiations via th...

29 February 2024

Biotechnology
Aclarion Technology Advances Global Validation with First Nociscan Exams in LIFEHAB Trial on Low Back Pain
New York, September 10, 2024 - PRISM MediaWire - Aclarion, Inc. (Nasdaq: ACON), a healthcare technology company focused on leveraging biomarkers and augmented intelligence to identify chronic low back pain, announced the completion of the first exams in its ongoing LIFEH...

Biotechnology
Understanding Autism Spectrum Disorder in Children: Insights and Advances in Treatment

New York, March 08, 2024 - PRISM MediaWire - Autism Spectrum Disorder (ASD) is a complex neurodevelopmental condition characterized by challenges in social interaction, communication, and repetitive behaviors. It affects individuals differently and can range from mild to...

8 March 2024

Biotechnology
Lipella Pharmaceuticals to Progress Development of Oral Graft-versus-Host-Disease Treatment Candidate

New York, March 06, 2024 - PRISM MediaWire - "Lipella Pharmaceuticals Inc. (Nasdaq: LIPO) secures FDA Approval for Investigational New Drug (IND) Application, Advancing Clinical Testing of LP-410 for Oral Graft-Versus-Host Disease (GvHD) Treatment. Clinical Study Set to ...

6 March 2024

Biotechnology
IceCure's ProSense® Achieves Complete Tumor Reduction in Early-Stage Breast Cancer

New York, March 06, 2024 - PRISM MediaWire - IceCure Medical Ltd. (Nasdaq: ICCM) has disclosed novel findings from an initial, autonomous breast cancer investigation, revealing a median tumor reduction of 100% at both six and twelve months subsequent to cryoablation in w...

6 March 2024

Biotechnology
Quoin Pharmaceuticals Expands Rare Disease Clinical Trials to Encompass Teen Patients

New York, March 04, 2024 - PRISM MediaWire - Clinical-stage biotechnology firm Quoin Pharmaceuticals (Nasdaq: QNRX) has obtained FDA clearance to enroll subjects aged 14 years and above into its two ongoing clinical trials for QRX003. These trials are dedicated to assess...

4 March 2024

Biotechnology
NeuroBo Pharmaceuticals to Commence Clinical Trial Addressing Obesity

New York, March 04, 2024 - PRISM MediaWire - NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO) has obtained Institutional Review Board (IRB) approval to advance its Phase 1 clinical trial of DA-1726, targeting obesity treatment. Anticipated commencement of patient randomizati...

4 March 2024

Biotechnology
Enveric Biosciences Makes Strides in Mental Health Treatment, Witnesses 127% Surge in Shares through Out-Licensing of Compound Classes

New York, N.Y., February 29, 2024 - PRISM MediaWire - Enveric Biosciences (NASDAQ: ENVB), a biotechnology firm specializing in the development of neuroplastogenic small-molecule therapeutics for mental health disorders, has announced the initiation of negotiations via th...

29 February 2024

Subscribe

Let's stay in touch!
We use cookies to run our website, analyze your use of our services, manage your online preference & personalize ad content. By accepting our cookies, you’ll get relevant content and social media features, personalized ads, and an enhanced browsing experience. To manage your choices, click „Cookie Settings”. Necessary cookies are required for the core website functionality and cannot be rejected. For more information, see our Cookie Policy.
Cookie settings
Cookies used on the site are categorized and below you can read about each category and allow or deny some or all of them, except for Necessary Cookies which are required to provide core website functionality. When categories that have been previously allowed are disabled, all cookies assigned to that category will be removed from your browser. You can see a list of cookies assigned to each category and detailed information on those cookies in the “Cookie Policy” tab.
Necessary cookies
Some cookies are required to provide core functionality. The website won't function properly without these cookies and they are enabled by default and cannot be disabled.
Preferences
Preference cookies enables the website to remember information to customize how the website looks or behaves for each user. This may include storing selected currency region, language or color theme.
Analytical cookies
Analytical cookies help us improve our website by collecting and reporting information on its usage.
Marketing cookies
Marketing cookies are used to track visitors across websites to allow publishers to display relevant and engaging advertisements. By enabling marketing cookies, you grant permission for personalized advertising across various platforms.